Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The syllogistic process that led us all to accept the utility of ASA in prevention of CVD in diabetics seemed innocent enough: a) ASA reduces CV events in persons with CVD, and b) diabetes is considered a CV risk equivalent; therefore, c) ASA must reduce CV events in persons with diabetes.

Clinical Briefs By Louis Kuritzky, MD